登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，6月5日，Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-06

  • Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

    Xin Xu, Jian Sun, Sheng Nie, Huiyuan Li, Yaozhong Kong, Min Liang, Jinlin Hou, Xianzhong Huang, Dongfeng Li, Tean Ma, Jiaqing Peng, Shikui Gao, Yong Shao, Hong Zhu, Johnson Yiu-Nam Lau, Guangyu Wang, Chunbao Xie, Li Jiang, Ailong Huang, Zhenglin Yang, Kang Zhang & Fan Fan Hou

    Nature Medicine (2020)

    Abstract

    Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased.

  • 原文来源：https://www.nature.com/articles/s41591-020-0949-6
17浏览量
原文链接
相关报告

  • 《bioRxiv，6月6日，Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-09
    • Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells Shane Miersch, Mart Ustav, Zhijie Li, James B. Case, Safder Ganaie, Giulia Matusali, Francesca Colavita, Daniele Lapa, Maria R. Capobianchi, View ORCID ProfileGuiseppe Novelli, Jang B. Gupta, Suresh Jain, Pier Paolo Pandolfi, Michael S. Diamond, Gaya Amarasinghe, James M. Rini, Sachdev S. Sidhu doi: https://doi.org/10.1101/2020.06.05.137349 Abstract Coronaviruses (CoV) are a large family of enveloped, RNA viruses that circulate in mammals and birds but have crossed the species barrier to infect humans seven times. Of these, three pathogenic strains have caused zoonotic infections in humans that result in severe respiratory syndromes including the Middle East Respiratory Syndrome (MERS-CoV), severe acute respiratory syndrome (SARS-CoV), and now SARS-CoV-2 coronaviruses, the latter of which is the cause of the ongoing pandemic of coronavirus disease 2019 (COVID-19). Here, we describe a panel of synthetic monoclonal antibodies, built on a human framework, that bind SARS-CoV-2 spike protein, compete for binding with ACE2, and potently inhibit infection by SARS-CoV-2. These antibodies were found to have a range of neutralization potencies against live virus infection in Vero E6 cells, potently inhibiting authentic SARS-CoV-2 virus at sub-nanomolar concentrations. These antibodies represent strong immunotherapeutic candidates for treatment of COVID-19. Competing Interest Statement S.S, P.P.P and S.J, are cofounders of Virna Therapeutics. The company is developing novel therapies for COVID-19 and other viruses.
    147浏览量
    原文链接

  • 《Nature，10月29日，Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-11-18
    • Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates Tiancheng Liu, Jessica Hsiung, Su Zhao, Jessica Kost, Deepika Sreedhar, Carl V. Hanson, Kjerstie Olson, Douglas Keare, Shin Ting Chang, Kevin P. Bliden, Paul A. Gurbel, Udaya S. Tantry, John Roche, Cynthia Press, John Boggs, Jorge P. Rodriguez-Soto, Jose G. Montoya, Meijie Tang & Hongjie Dai Nature Biomedical Engineering (2020) Abstract Accurate assays for the detection of antibodies to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) are essential for the control of the COVID-19 (coronavirus disease 2019) pandemic. Here, we report antibody and antibody-avidity assays, relying on near-infrared-fluorescence amplification by nanostructured plasmonic gold substrates, for the simultaneous detection of antibodies to the S1 subunit of the spike protein and to the receptor binding domain of SARS-CoV-2 in human serum and saliva, and for quantifying immunoglobulin avidities against coronavirus antigens from SARS-CoV-2, SARS-CoV-1 and the common-cold viruses OC43, HKU1, NL63 and 229E. The antibody assay detected immunoglobulin M in 87% (52 of 60) COVID-19-positive serum samples collected 6 or more days after symptom onset (and the immunoglobulins M and G in all 33 samples collected at least 15 days after symptom onset), and correctly classified 456 out of the 457 COVID-19-negative serum samples tested (424 of them collected before the pandemic, including 73 that were positive for other viruses). We used the antibody-avidity assay to study antibody-maturation patterns, anamnestic responses, and cross-immunity to the common-cold coronaviruses.
    25浏览量
    原文链接